Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a sleep apnea machine match the gold standard in detecting breathing pauses?

NCT ID NCT06317077

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study evaluates whether prismaLINE PAP devices accurately count breathing events (apneas and hypopneas) compared to the gold-standard polysomnography (PSG) in people with sleep apnea. Participants will use a full face mask during a titration night, where the device briefly lowers pressure to provoke breathing events. The goal is to see if the device's apnea-hypopnea index (AHI) matches the manually scored PSG, and to confirm the safety and performance of the device and mask.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PAP therapy with subtherapeutic phases to provoke breathing events, using Löwenstein Medical full face masks
What this could lead to
If successful, this could confirm that prismaLINE devices reliably measure breathing events, potentially improving home monitoring of sleep apnea therapy.
What could go wrong
This is a small, early-stage device validation study, not a treatment trial. Results may not apply to other devices or mask types, and the induced breathing events may not reflect real-world conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

49 people

The number who actually took part.

Started

Dec 2024

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Polysomnographic diagnosis performed at the investigator site * Indication for CPAP therapy (initial setting) * Age of the participants: ≥ 18 ≤ 80 years * AHI diagnosis night ≥ 15/h * Capacity to consent * Agreement to use a full face mask of Löwenstein Medical during the titration night * Existence of a signed informed consent form for participation in the clinical investigation and a signed declaration of consent for the use of data within the scope of the DSGVO Exclusion Criteria: * Presence of a contraindication to CPAP therapy * Participation in another clinical investigation that influences the adjustment to CPAP therapy by stipulate device settings or titration * pregnant or breastfeeding woman Inclusion Criteria Statistical Evaluation: * AHI PSG (diagnosis and therapy) and AHI of the device (therapy) are completely available * Evaluation of the mask/device functionalities is available * Clear documentation of (predictable) adverse events and (predictable) adverse device effects * Existence of a signed informed consent form for participation in the clinical investigation and a signed declaration of consent for the use of data within the scope of the DSGVO * Reliable evaluation of the polysomnography (titration night) is possible: no missing signals, good signal quality, no deviation of the applied CPAP pressure course from the course specified for the clinical investigation * Total sleep time during the titration night ≥ 4 hrs * Proportion of the therapy time with high leakage (more than 50 l/min) \< 10% * The quality assurance process did not identify any deviations from the source data that could not be corrected

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sleep apnea syndromes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Krankenhaus Bethanien

    Solingen, North Rhine-Westphalia, 42699, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.